Xenografts derived from patients with head and neck cancer recapitulate patient tumour properties

Makita,Haruna; Endo,Kazuhira; Kasahara,Yoshiya; Nakata,Asuka; Moriyama‑Kita,Makiko; Ishikawa,Kazuya; Ueno,Takayoshi; Nakanishi,Yosuke; Kondo,Satoru; Wakisaka,Naohiro; Gotoh,Noriko; Yoshizaki,Tomokazu

doi:10.3892/ol.2021.12646

Xenografts derived from patients with head and neck cancer recapitulate patient tumour properties

Authors:
- Haruna Makita
- Kazuhira Endo
- Yoshiya Kasahara
- Asuka Nakata
- Makiko Moriyama‑Kita
- Kazuya Ishikawa
- Takayoshi Ueno
- Yosuke Nakanishi
- Satoru Kondo
- Naohiro Wakisaka
- Noriko Gotoh
- Tomokazu Yoshizaki
View Affiliations

Affiliations: Department of Otolaryngology‑Head and Neck Surgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Ishikawa 920‑8640, Japan, Department of Cancer Cell Biology, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa 920‑1192, Japan
Published online on: March 16, 2021 https://doi.org/10.3892/ol.2021.12646
Article Number: 385
Copyright: © Makita et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Rodent models mimic the heterogeneity of head and neck cancer (HNC) malignancies and are used to investigate HNC‑associated biomarkers and evaluate drug responses. To assess the utility of patient‑derived xenografts (PDXs) as an HNC model, 18 tumour samples were obtained from surgical specimens of patients with HNC and implanted into non‑obese diabetic severe combined immunodeficient mice. The histological features of PDXs and corresponding patient samples were compared. Furthermore, the present study investigated how PDX responses to anticancer drugs mimic patient clinical responses, as well as the expression of adenosine triphosphate‑binding cassette transporters through chemotherapy in an HNC‑PDX model. A total of five PDXs from patients with HNC exhibiting high correspondence with histopathological features of the original patient samples were established (establishment rate, 28%). The responses of three PDXs to cisplatin were associated with clinical responses of the patients. ABC transporter expression was augmented in one PDX model after anticancer drug treatment, but not in PBS‑treated passaged PDXs. PDX models exhibited similar biological and chemosensitive characteristics to those of the primary tumours. PDXs could be a useful preclinical tool to test novel therapeutic agents and identify novel targets and biomarkers in HNC.

View Figures

View References

1	DiMasi JA, Reichert JM, Feldman L and Malins A: Clinical approval success rates for investigational cancer drugs. Clin Pharmacol Ther. 94:329–335. 2013. View Article : Google Scholar : PubMed/NCBI
2	Jung J, Seol HS and Chang S: The generation and application of patient-derived xenograft model for cancer research. Cancer Res Treat. 50:1–10. 2018. View Article : Google Scholar : PubMed/NCBI
3	Peng S, Creighton CJ, Zhang Y, Sen B, Mazumdar T, Myers JN, Lai SY, Woolfson A, Lorenzi MV, Bell D, et al: Tumor grafts derived from patients with head and neck squamous carcinoma authentically maintain the molecular and histologic characteristics of human cancers. J Transl Med. 11:1982013. View Article : Google Scholar : PubMed/NCBI
4	Vrana D, Hlavac V, Brynychova V, Vaclavikova R, Neoral C, Vrba J, Aujesky R, Matzenauer M, Melichar B and Soucek P: ABC transporters and their role in the neoadjuvant treatment of esophageal cancer. Int J Mol Sci. 19:8682018. View Article : Google Scholar
5	Theile D, Gal Z, Warta R, Rigalli JP, Lahrmann B, Grabe N, Herold Mende C, Dyckhoff G and Weiss J: Antiproliferative efficacies but minor drug transporter inducing effects of paclitaxel, cisplatin, or 5-fluorourcil in a murine xenograft model for head and neck squamous cell carcinoma. Cancer Biol Ther. 15:436–442. 2014. View Article : Google Scholar : PubMed/NCBI
6	Warta R, Theile D, Mogler C, Herpel E, Grabe N, Lahrmann B, Plinkert PK, Herolde-Mende C, Weiss J and Dyckhoff G: Association of drug transporter expression with mortality and progression-free survival in stage IV head and neck squamous cell carcinoma. PLos One. 9:e1089082014. View Article : Google Scholar : PubMed/NCBI
7	Brierley JD, Gospodarowicz MK and Wittekind C: UICC TNM Classification of Malignant Tumours. 8th edition. Wiley Blackwell; New York, NY: 2017
8	Tanabe H, Takada Y, Minegishi D, Kurematsu M, Masui T and Mizusawa H: Cell line individualization by STR multiplex system in the cell bank found cross-contamination between ECV304 and EJ-1/T24. Tiss Cult Res Commun. 18:329–338. 1999.
9	Cho YB, Hong HK, Choi YL, Oh E, Joo KM, Jin J, Nam DH, Ko YH and Lee WY: Colorectal cancer patient-derived xenografted tumors maintain characteristic features of the original tumors. J Surg Res. 187:502–509. 2014. View Article : Google Scholar : PubMed/NCBI
10	Klinghammmer K, Raguse JD, Plath T, Albers AE, Joehrens K, Zakameh A, Brzezicha B, Wulf-Goldenberg A, Keilholz U, Hoffmann J and Fichtner I: A comprehensively characterized large panel of head and neck cancer patient-derived xenografts identifies the mTOR inhibitor everolimus as potential new treatment option. Int J Cancer. 136:2940–2948. 2015. View Article : Google Scholar : PubMed/NCBI
11	Kimple RJ, Harari PM, Torres AD, Yang RZ, Soriano BJ, Yu M, Armstrong EA, Blitzer GC, Smith MA, Lorenz LD, et al: Development and characterization of HPV-positive and HPV-negative head and neck squamous cell carcinoma tumorgrafts. Clin Cancer Res. 19:855–864. 2013. View Article : Google Scholar : PubMed/NCBI
12	Stewart EL, Mascaux C, Pham NA, Sakashita S, Sykes J, Kim L, Yanagawa N, Allo G, Ishizawa K, Wang D, et al: Clinical utility of patient-derived xenografts to determine biomarkers of prognosis and map resistance pathways in EGFR-mutant lung adenocarcinoma. J Clin Oncol. 33:2472–2480. 2015. View Article : Google Scholar : PubMed/NCBI
13	Garrido-Laguna I, Uson M, Rajeshkumar NV, Tan AC, de Oliveira E, Karikari C, Villaroel MC, Salomon A, Taylor G, Sharma R, et al: Tumor engraftment in nude mice and enrichment in stroma-related gene pathways predicts poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin Cancer Res. 17:5793–5800. 2011. View Article : Google Scholar : PubMed/NCBI
14	Pergolini I, Morales-Oyarvide V, Mino-Kenudson M, Honselmann KC, Rosenbaum MW, Nahar S, Kem M, Ferrone CR, Lillemoe KD, Bardeesy N, et al: Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival. PLoS One. 12:e01828552017. View Article : Google Scholar : PubMed/NCBI
15	Facompre ND, Sahu V, Montone KT, Harmeyer KM, Nakagawa H, Rustgi AK, Weinstein GS, Gimotty PA and Basu D: Barriers to generating PDX models of HPV-related head and neck cancer. Laryngoscope. 127:2777–2783. 2017. View Article : Google Scholar : PubMed/NCBI
16	Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF and Ailles LE: Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA. 104:973–978. 2007. View Article : Google Scholar : PubMed/NCBI
17	Yu J, Qin B, Moyer AM, Sinnwell JP, Thompson KJ, Copland JA III, Marlow LA, Miller JL, Yin P, Gao B, et al: Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study. Breast Cancer Res. 19:1302017. View Article : Google Scholar : PubMed/NCBI
18	Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L and Lewis JL Jr: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 9:389–393. 1991. View Article : Google Scholar : PubMed/NCBI
19	Harries M and Gore M: Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease. Lancet Oncol. 3:537–545. 2002. View Article : Google Scholar : PubMed/NCBI
20	Knoedler M, Gauler TC, Gruenwald V, Matzdorff A, Schroeder M, Dietz A, Jordan WO, Arnold D, Hennemann B, Hofele C, et al: Phase II study of cetuximab in combination with docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after platinum-containing therapy: A multicenter study of the Arbeitsgemeinschaft Internistische Onkologie. Oncology. 84:284–289. 2013. View Article : Google Scholar : PubMed/NCBI
21	Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, Dummer R, McMahon M and Stuart DD: Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature. 494:251–255. 2013. View Article : Google Scholar : PubMed/NCBI